169 related articles for article (PubMed ID: 37204338)
1. APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.
Evans CD; Sparks J; Andersen SW; Brooks DA; Hauck PM; Mintun MA; Sims JR
Alzheimers Dement; 2023 Dec; 19(12):5407-5417. PubMed ID: 37204338
[TBL] [Abstract][Full Text] [Related]
2. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
Kennedy RE; Cutter GR; Schneider LS
Alzheimers Dement; 2014 May; 10(3):349-59. PubMed ID: 23712001
[TBL] [Abstract][Full Text] [Related]
3. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.
Nemes S; Logan PE; Manchella MK; Mundada NS; La Joie R; Polsinelli AJ; Hammers DB; Koeppe RA; Foroud TM; Nudelman KN; Eloyan A; Iaccarino L; Dorsant-Ardón V; Taurone A; Thangarajah M; Dage JL; Aisen P; Grinberg LT; Jack CR; Kramer J; Kukull WA; Murray ME; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Vemuri P; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Riddle M; Rogalski E; Salloway S; Sha SJ; Turner RS; Wingo TS; Womack KB; Wolk DA; Rabinovici GD; Carrillo MC; Dickerson BC; Apostolova LG;
Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S49-S63. PubMed ID: 37496307
[TBL] [Abstract][Full Text] [Related]
4. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.
Suzuki K; Hirakawa A; Ihara R; Iwata A; Ishii K; Ikeuchi T; Sun CK; Donohue M; Iwatsubo T;
Alzheimers Dement (N Y); 2020; 6(1):e12007. PubMed ID: 32211510
[TBL] [Abstract][Full Text] [Related]
5. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
[TBL] [Abstract][Full Text] [Related]
6. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
[TBL] [Abstract][Full Text] [Related]
7. Beneficial Effect of Societal Factors on APOE-ε2 and ε4 Carriers' Brain Health: A Systematic Review.
Aravena JM; Lee J; Schwartz AE; Nyhan K; Wang SY; Levy BR
J Gerontol A Biol Sci Med Sci; 2024 Feb; 79(2):. PubMed ID: 37792627
[TBL] [Abstract][Full Text] [Related]
8. Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Cheng YC; Huang YC; Liu HC
Dement Geriatr Cogn Disord; 2018; 45(5-6):335-352. PubMed ID: 30041236
[TBL] [Abstract][Full Text] [Related]
9. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.
Farlow M; Lane R; Kudaravalli S; He Y
Pharmacogenomics J; 2004; 4(5):332-5. PubMed ID: 15289797
[TBL] [Abstract][Full Text] [Related]
10. APOE ε4, Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia.
Blackman J; Love S; Sinclair L; Cain R; Coulthard E
Alzheimers Res Ther; 2022 Mar; 14(1):47. PubMed ID: 35354468
[TBL] [Abstract][Full Text] [Related]
11. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
Loomis SJ; Miller R; Castrillo-Viguera C; Umans K; Cheng W; O'Gorman J; Hughes R; Budd Haeberlein S; Whelan CD
Neurology; 2024 Feb; 102(3):e207919. PubMed ID: 38165296
[TBL] [Abstract][Full Text] [Related]
12. Association of
Qian J; Betensky RA; Hyman BT; Serrano-Pozo A
Neurology; 2021 May; 96(19):e2414-e2428. PubMed ID: 33771840
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
Jeremic D; Navarro-López JD; Jiménez-Díaz L
Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
[TBL] [Abstract][Full Text] [Related]
14. Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status.
Malek-Ahmadi M; Beach T; Obradov A; Sue L; Belden C; Davis K; Walker DG; Lue L; Adem A; Sabbagh MN
Curr Alzheimer Res; 2013 Jul; 10(6):654-9. PubMed ID: 23627755
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
16. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.
Rigaud AS; Traykov L; Caputo L; Guelfi MC; Latour F; Couderc R; Moulin F; de Rotrou J; Forette F; Boller F
Eur J Neurol; 2000 May; 7(3):255-8. PubMed ID: 10886308
[TBL] [Abstract][Full Text] [Related]
17. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR;
N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891
[TBL] [Abstract][Full Text] [Related]
18. Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results.
Moreno-Grau S; Rodríguez-Gómez O; Sanabria Á; Pérez-Cordón A; Sánchez-Ruiz D; Abdelnour C; Valero S; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Lafuente A; Gil S; Santos-Santos MÁ; Alegret M; Espinosa A; Ortega G; Guitart M; Gailhajanet A; de Rojas I; Sotolongo-Grau Ó; Ruiz S; Aguilera N; Papasey J; Martín E; Peleja E; ; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MÁ; Giménez J; Serrano-Ríos M; Orellana A; Tárraga L; Ruiz A; Boada M;
Alzheimers Dement; 2018 May; 14(5):634-643. PubMed ID: 29156223
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.
Premkumar DR; Cohen DL; Hedera P; Friedland RP; Kalaria RN
Am J Pathol; 1996 Jun; 148(6):2083-95. PubMed ID: 8669492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
